KATHERINE KELLY: Open Payments
NPI 1659315315 · COLUMBUS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,206 in 50 payments from 12 companies in 2025. Trend: 2023 $955 · 2024 $849 · 2025 $1,206
Food & beverage: $1,198Education: $8
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $461 |
| Vanda Pharmaceuticals Inc. | 13 | $293 |
| Neurocrine BioSciences, Inc. | 6 | $97 |
| ACADIA Pharmaceuticals Inc | 1 | $96 |
| Alkermes, Inc. | 3 | $59 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| E.R. Squibb & Sons, L.L.C. | 2 | $30 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $27 |
| ABBVIE INC. | 1 | $26 |
Products named: UZEDY, FANAPT, INGREZZA, NUPLAZID, AUSTEDO XR, ARISTADA, Auvelity, COBENFY.
Industry payments across IN — which companies pay providers there.
